<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306553</url>
  </required_header>
  <id_info>
    <org_study_id>CYT004-MelQbG10 03</org_study_id>
    <nct_id>NCT00306553</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytos Biotechnology AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytos Biotechnology AG</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate a specific cellular immune response in melanoma
      patients that have been vaccinated with a Melan-A VLP vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Malignant Melanoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CYT004-MelQbG10</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide written informed consent.

          -  Able and willing to complete all protocol requirements.

          -  Age: 18 years and older.

          -  Histological confirmed stage III or IV melanoma.

          -  At least one confirmed detectable target lesion

          -  HLA-A*0201 haplotype

          -  Expected survival of at least 6 months.

          -  Full recovery from surgery.

          -  Able to undergo either CT scan or MRI scan for tumor assessment.

          -  Wash-out period of 4 weeks after chemotherapy

          -  All AEs form prior anticancer therapy have resolved to ≤ Grade 1.

          -  Sexually active males should use adequate contraception throughout the study period
             and 3 months thereafter.

          -  Females of child bearing potential should use adequate contraception throughout the
             study period and 3 months thereafter, that can be oral contraception or a
             double-barrier local contraception (intra-uterine device plus condom or spermicidal
             gel plus condom), and have a negative serum pregnancy test within 4 weeks prior to the
             first dose of the vaccine.

        Exclusion Criteria:

          -  Pregnant or nursing.

          -  Use of an investigational drug within 30 days before enrolment.

          -  Known or suspected brain metastases.

          -  Current use of an immunosuppressive drug or any concomitant medication that could
             potentially interfere with the study drug

          -  Presence of significant cardiovascular, renal, pulmonary, endocrine, infectious,
             neurological or bone marrow function disorders

          -  Serum tests positive for HIV, HBV, HCV.

          -  Active autoimmune diseases or severe allergies.

          -  Current diagnosis or history of relevant and severe psychiatric disorder that
             compromises the patient’s ability to understand the patient information, to give
             informed consent, to comply with the trial protocol or to complete the study.

          -  Abuse of alcohol or other recreational drugs.

          -  Previous vaccination with a Melan-A analog peptide.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Alexander Knuth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Oncology, Univerity Hospital Zuerich, CH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Dermatology, USZ</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Oncology, USZ</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2006</study_first_submitted>
  <study_first_submitted_qc>March 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2006</study_first_posted>
  <last_update_submitted>September 18, 2006</last_update_submitted>
  <last_update_submitted_qc>September 18, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

